21:30 , Nov 10, 2017 |  BC Week In Review  |  Financial News

EOC Pharma raises $32M series B

On Nov. 7, EOC Pharma Group (Shanghai, China) raised $32 million in a series B round led by new investor Taikang. Fellow new investor H&Q Asia Pacific also participated, as did existing investor Sequoia China....
18:23 , Nov 7, 2017 |  BC Extra  |  Financial News

EOC Pharma raises $32M series B

EOC Pharma Group (Shanghai, China) raised $32 million in a series B round led by new investor Taikang. Fellow new investor H&Q Asia Pacific also participated, as did existing investor Sequoia China. EOC Pharma, a...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

ACT Biotech, Eddingpharm deal

Eddingpharm acquired exclusive, worldwide rights to develop and commercialize oncology compounds telatinib, ACTB1003 and ACTB1010 from ACT Biotech. Eddingpharm said the deal includes "several hundred" compounds from the same family as the three leads. ACT...
08:00 , Feb 25, 2013 |  BC Week In Review  |  Company News

Curis management update

Curis Inc. (NASDAQ:CRIS), Lexington, Mass.   Business: Cancer   Hired: Ali Fattaey as president and COO, formerly president and CEO of ACT Biotech Inc.  ...
08:00 , Dec 12, 2011 |  BC Week In Review  |  Company News

Pharmacyclics management update

Pharmacyclics Inc. (NASDAQ:PCYC), Sunnyvale, Calif.   Business: Cancer, Autoimmune   Hired: Lori Kunkel as CMO, formerly CMO of ACT Biotech Inc.  ...
08:00 , Dec 12, 2011 |  BC Week In Review  |  Clinical News

Telatinib: Additional Phase II data

An analysis of serum samples from 28 evaluable patients in the open-label, U.S. and Spanish Phase II TEL0805 trial showed that both PFS and OS were significantly longer in patients who had a >=33% reduction...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Clinical News

Telatinib: Phase I data

A dose-escalation, European Phase I trial in 39 patients with refractory colorectal cancer showed that twice-daily >=600 mg oral telatinib led to tumor shrinkage in 41% of patients, plus 22 cases of stable disease. Telatinib...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Clinical News

Telatinib: Final Phase II data

Final data from the open-label, U.S. and Spanish Phase II TEL0805 trial in 39 patients showed that first-line treatment with twice-daily oral telatinib plus capecitabine and cisplatin led to an ORR of 67%, including 1...
07:00 , May 9, 2011 |  BioCentury  |  Emerging Company Profile

ACT: ACTing selectively

Tyrosine kinase inhibitors that target VEGF receptor have revolutionized the treatment of renal cell carcinoma (RCC). However, off-target effects have resulted in little success of the first-generation drugs in other solid tumors aside from two...
08:00 , Mar 7, 2011 |  BC Week In Review  |  Clinical News

Telatinib: SPA submitted

ACT Biotech submitted an SPA to FDA for a planned double-blind, placebo-controlled Phase III trial to compare telatinib plus chemotherapy vs. chemotherapy alone in 700 patients. ACT Biotech Inc. , San Francisco, Calif.   Product:...